KURA
Kura Oncology, Inc.
Key Financials
Operating Income
$-303631000
↓ 57.2%
Revenue
$67.5M
↑ 25.2%
EPS (Diluted)
$-3.18
↓ 57.4%
Net Income
$-278666000
↓ 60.2%
Total Assets
$738.4M
↓ 2.9%
Cash & Equivalents
$149.1M
↓ 33.6%
Shareholders' Equity
$174.1M
↓ 57.9%
Total Liabilities
$564.2M
↑ 62.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/22/2026 | View on SEC |
| 144 | 6/18/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| S-8 | 6/4/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KURA |
| Company Name | Kura Oncology, Inc. |
| CIK | 1422143 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 500-8800 |